Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer.
Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Miyaaki H, Nakao K, Shitara K.
Jubashi A, et al. Among authors: matsubara y.
Gastric Cancer. 2025 Jan;28(1):63-73. doi: 10.1007/s10120-024-01560-z. Epub 2024 Nov 2.
Gastric Cancer. 2025.
PMID: 39487862
Free PMC article.